Results 51 to 60 of about 70,538 (300)

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients [PDF]

, 2017
Immunoglobulin replacement therapy (IRT) is standard treatment for patients with primary immunodeficiency (PID). Because most of the patients with PID will require long life-time immunoglobulin replacement therapy, the quality of the prescribed ...
Alfa Cissé, Ousmane, Bernatowska, Ewa, Jolles, Stephen, Krivan, Gergely, Lopes Granados, Eduardo, Ouaja, Rabye, Paolantonacci, Phillipe   +6 more
core  

Intravenous immunoglobulin replacement therapy in X-linked agammaglobulinemia.

Japanese Journal of Clinical Immunology, 2002
Intravenous immunoglobulin (IVIG) replacement therapy is the mainstay of therapy for X linked agammaglobulinemia (XLA). This study was attempted to investigate how patients with XLA were treated with IVIG in Japan. Data were complied from questionnaires filled in by the physicians.
Hirokazu, Kanegane, Keiko, Nomura, Takeshi, Futatani, Toshio, Miyawaki   +3 more
openaire   +3 more sources

The cooperative regulation of miR‐221 by APE1 and AUF1 impacts p27Kip1 defining a miR signature relevant for cervical cancer

FEBS Open Bio, EarlyView.
A regulatory axis involving APE1, AUF1, and miR‐221 is proposed. Pri‐miR‐221 is processed by DROSHA and DICER to generate mature miR‐221, which targets p27Kip1 mRNA. APE1 and AUF1 compete for pre‐miR‐221 binding. Reduced APE1/AUF1 levels impair miR‐221 biogenesis, decrease p27Kip1 mRNA degradation, and promote cell cycle progression, chemoresistance ...
Matilde Clarissa Malfatti, Nicolò Gualandi, Gianluca Tell, Giulia Antoniali   +3 more
wiley   +1 more source

Thymus transplantation for complete DiGeorge syndrome: European experience [PDF]

, 2017
Background: Thymus transplantation is a promising strategy for the treatment of athymic complete DiGeorge syndrome (cDGS). Methods: Twelve patients with cDGS were transplanted with allogeneic cultured thymus.
Adrian J. Thrasher, Alina Papadopol, Amrolia, Anderson, Anna Furmanski, Austen Worth, Blythe Devlin, David M. Sansom, Davies, Despina Moshous, E. Graham Davies, Elizabeth McCarthy, Furmanski, H. Bobby Gaspar, Hans Christian Erichsen, Hassan, Hassan, Heino, Ida Ricciardelli, Janda, Jesmeen Maimaris, Joe Curry, Jolanta Bernatoniene, Kathryn L. Parsley, Kim Neuling, Kimberly Gilmour, King, Konstantinos Mengrelis, Lizzie Hutchison, Luigi Poliani, M. Louise Markert, Malgorzata Pac, Marianne Ifversen, Markert, Markert, Markert, Markert, Markert, Markert, Markert, McGhee, Melissa Cheung, Michael Browning, Morbach, Morbach, Neil Halliday, Neil Sebire, Poliani, Ronald Bremner, Rucci, Ryan, Schubert, Shearer, Shearer, Stuart Adams, T. Ronan Leahy, Tessa Crompton, Tiia Voor, Winnie Ip, Yang   +59 more
core   +3 more sources

Development of human monoclonal antibodies against TARM1 by yeast display

FEBS Open Bio, EarlyView.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe, Mayumi Saeki, Masaaki Hashiguchi, Sayaka Ono, Kazuhisa Aoki, Hidetaka Tanno   +5 more
wiley   +1 more source

Guillain-Barré syndrome: a century of progress [PDF]

, 2016
In 1916, Guillain, Barré and Strohl reported on two cases of acute flaccid paralysis with high cerebrospinal fluid protein levels and normal cell counts — novel findings that identified the disease we now know as Guillain–Barré syndrome (GBS).
A Campbell, A Chiba, A Chiba, A Pestronk, A Uncini, AA Ilyas, AD Langmuir, AJ Sumner, AK Asbury, AK Asbury, AK Asbury, AM Fitzpatrick, B Parra, B van den Berg, BH Waksman, C Brechenmacher, C Fokke, C Hafer-Macko, C Linington, CE Hafer-Macko, CL Schengrund, CP O'Leary, E Díez-Tejedor, FG van der Meché, FH Geisler, G Guillain, GM McKhann, GM O'Hanlon, H Wis´niewski, HJ Willison, Hugh J. Willison, J Kaldor, J Matias-Guiu, JA Goodfellow, JC Dodge, JG McLeod, JH Rees, JJ Plomp, JM Pearce, John A. Goodfellow, JW Albers, JW Griffin, JW Prineas, K Kaida, K Susuki, KE Astrom, KM Rhodes, KN Greenshields, LB Schonberger, LD Osler, LM Araujo, LT Kurland, M Fisher, M Kadlubowski, M Vermeulen, MK White, N Shahrizaila, N Yuki, N Yuki, N Yuki, N Yuki, NA Gregson, O Landry, PA van Doorn, PO Osterman, R McGonigal, R McGonigal, R van Koningsveld, RA Hughes, RA Hughes, RJ Greenwood, RP Kleyweg, S Draganescu, S Kusunoki, S Lafontaine, S Rinaldi, S Rinaldi, S Rinaldi, SK Halstead, SK Halstead, SK Halstead, T Lasky, T Saida, TE Feasby, TE Feasby, TW Ho, TW Ho, VM Cao-Lormeau, W Wiederholt, W Yan, WE Haymaker, Y Nagai   +91 more
core   +1 more source

Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells

FEBS Open Bio, EarlyView.
This study explores the feasibility of expressing the antitumoral protein Amblyomin‐X through a suicide gene therapy approach and investigates its intracellular fate after gene delivery. Although the gene is efficiently expressed, melanoma cells rapidly degrade the Amblyomin‐X protein via proteasome activity.
Victor Dal Posolo Cinel, Carlos DeOcesano Pereira, Aline Ramos Maia Lobba, Melissa Regina Fessel, Ana Marisa Chudzinski‐Tavassi   +4 more
wiley   +1 more source

Human normal immunoglobulin in the treatment of primary immunodeficiency diseases

Therapeutics and Clinical Risk Management, 2012
Philip WoodSt James University Hospital, Leeds, United KingdomAbstract: The primary antibody deficiency syndromes are a rare group of disorders that can present at any age, and for which delay in diagnosis remains common.
Wood P
doaj  

Lifelong immunoglobulin replacement is not always necessary: A case description of a patient with recurrent infections and hypogammaglobulinemia

International Journal of Immunopathology and Pharmacology, 2019
Humoral immunodeficiency with accompanying infections is an indication for human immunoglobulin replacement therapy. Whether treatment will be lifelong or necessary only temporarily depends on the nature of deficiency: primary (persistent) or secondary ...
Katarzyna Napiorkowska-Baran, Radoslaw Janicki, Sylwia Koltan, Ewa Szynkiewicz, Zbigniew Bartuzi   +4 more
doaj   +1 more source